oxybutynin has been researched along with Disease Models, Animal in 44 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As a worst-case scenario for consequences of repeated application on neoplastic growth, the melanin-binding drug, rasagiline, was used in a transdermal formulation applied directly to a human-derived melanoma to determine the effects on tumor growth." | 7.78 | Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. ( Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J, 2012) |
| "To clarify the basic mechanism involved in the pathophysiology of cystitis by characterizing the urodynamic parameters, pharmacologically relevant (muscarinic and purinergic) receptors, and the in vivo release of adenosine triphosphate (ATP) in the bladder of hydrochloric acid (HCl)-treated rats." | 7.76 | Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. ( Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 7.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "We investigated the effects of AH-9700 (1-[2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl] pyrrolidine fumarate; a novel sigma receptor ligand), (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG) (two typical sigma receptor ligands), and oxybutynin (a currently used anti-pollakiuria drug) on cystometrograms in anesthetized rats with 30% acetone-induced cystitis." | 7.71 | Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis. ( Ishii, D; Kawashima, K; Oka, M; Shimizu, I, 2001) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 5.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| " As a worst-case scenario for consequences of repeated application on neoplastic growth, the melanin-binding drug, rasagiline, was used in a transdermal formulation applied directly to a human-derived melanoma to determine the effects on tumor growth." | 3.78 | Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo. ( Arjmand, FM; Christianson, C; Dines, K; Hamlin, R; Huang, B; Meier-Davis, SR; Nagata, T; Shudo, J; Wen, J, 2012) |
| "To clarify the basic mechanism involved in the pathophysiology of cystitis by characterizing the urodynamic parameters, pharmacologically relevant (muscarinic and purinergic) receptors, and the in vivo release of adenosine triphosphate (ATP) in the bladder of hydrochloric acid (HCl)-treated rats." | 3.76 | Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. ( Fujino, T; Kageyama, A; Nozawa, Y; Yamada, S; Yoshida, A, 2010) |
| "Tulobuterol patches are long-acting bronchodilators for percutaneous absorption including the β(2)-adrenoreceptor agonist tulobuterol, as a main ingredient, used for long-term management of pediatric asthma." | 3.76 | Comparative study of skin permeation profiles between brand and generic tulobuterol patches. ( Abe, T; Arisaka, O; Fukuda, H; Yoshihara, S, 2010) |
| " In this study, we investigated the effect of the recently developed P2X3 and P2X2/3 receptor antagonist A-317491 on cyclophosphamide (CYP)-induced cystitis to determine whether a P2X receptor antagonist could be beneficial for the treatment of bladder overactivity induced by CYP." | 3.74 | Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats. ( Ikeda, M; Ito, K; Iwami, A; Katsura, H, 2008) |
| "We investigated the effects of AH-9700 (1-[2-(3,4-dihydro-6,7-dimethyl-2-naphthalenyl)ethyl] pyrrolidine fumarate; a novel sigma receptor ligand), (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG) (two typical sigma receptor ligands), and oxybutynin (a currently used anti-pollakiuria drug) on cystometrograms in anesthetized rats with 30% acetone-induced cystitis." | 3.71 | Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis. ( Ishii, D; Kawashima, K; Oka, M; Shimizu, I, 2001) |
| " Furthermore, NS-21 increased the bladder capacity without suppressing micturition pressure, suggesting that NS-21 may be a more effective therapeutic drug than propiverine, oxybutynin or flavoxate for the treatment of urinary frequency and urinary incontinence." | 3.69 | Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. ( Hamada, K; Kimura, K; Kimura, Y; Sasaki, Y; Seto, T; Ukai, Y; Yamazaki, C; Yoshikuni, Y, 1997) |
| "A mouse model of wheat allergy has provided insights into effects of skin exposure to wheat protein; it is a plausible route of human sensitization for wheat anaphylaxis." | 1.62 | Assessment of Immune Responses in an Animal Model of Wheat Food Allergy via Epicutaneous Sensitization. ( Adachi, R; Kondo, K; Tamehiro, N, 2021) |
| " Nearly six-time enhancement of bioavailability was observed when alendronate was used in the nanoparticulate form in transdermal patches used with sonophoresis." | 1.56 | Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis. ( Huang, G; Li, B; Ma, Z; Qin, S, 2020) |
| "Development of an effective breast cancer vaccine can be a groundbreaking immunotherapeutic approach." | 1.51 | Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin. ( Akalkotkar, A; Chablani, L; D'Souza, MJ; Tawde, SA, 2019) |
| "Repairs of large to massive rotator cuff tears have a high failure rate." | 1.51 | Use of a Novel, Reinforced, Low Immunogenic, Porcine Small Intestine Submucosa Patch to Repair a Supraspinatus Tendon Defect in a Rabbit Model. ( Cho, E; Fang, Z; Huang, K; Huangfu, X; Jiang, J; Zhang, X; Zhao, J, 2019) |
| "Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist used to treat Alzheimer's disease." | 1.43 | Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats. ( Bae, CS; Cho, IH; Choi, BM; Kim, EJ; Kim, SH; Lee, SH; Noh, GJ; Noh, YH; Park, WD, 2016) |
| " Thus, the patch may serve as an alternative therapy to oral dosage form of simvastatin with outmost patient compliance." | 1.43 | Application of Response Surface Methodology for Design and Optimization of Reservoir-type Transdermal Patch of Simvastatin. ( Parhi, R; Patnaik, S; Suresh, P, 2016) |
| "Tadalafil treated bladders measured lower collagen content towards the end of the study, indicating an antifibrotic effect." | 1.42 | Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model. ( Maciejewski, CC; Metcalfe, PD; Tredget, EE, 2015) |
| "The study aimed to prepare a transdermal patch for flurbiprofen using isopulegol decanoate (ISO-C10) as a permeation enhancer, and to evaluate the in-vitro and in-vivo percutaneous permeation of the drug, as well as the pharmacodynamic efficacy of the formulation." | 1.42 | Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ( Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015) |
| "Oxybutynin treated animals also had decreased expression of amyloid beta 1-42 (82." | 1.35 | Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease? ( Fletcher, S; Klausner, AP; Neff, P; Sharma, S; Son, H; Steers, WD; Tuttle, JB; Yang, SK, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (4.55) | 18.2507 |
| 2000's | 6 (13.64) | 29.6817 |
| 2010's | 28 (63.64) | 24.3611 |
| 2020's | 8 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Babaoglu, M | 1 |
| Zumrutbas, AE | 1 |
| Acar, IC | 1 |
| Hatip, FB | 1 |
| Kucukatay, V | 1 |
| Eskicorapci, S | 1 |
| Aybek, Z | 1 |
| Maciejewski, CC | 1 |
| Tredget, EE | 1 |
| Metcalfe, PD | 1 |
| Kapoor, H | 1 |
| Gupta, E | 1 |
| Sood, A | 1 |
| Wada, N | 1 |
| Shimizu, T | 1 |
| Takai, S | 1 |
| Shimizu, N | 1 |
| Tyagi, P | 1 |
| Kakizaki, H | 1 |
| Yoshimura, N | 1 |
| Yoshida, A | 1 |
| Kageyama, A | 1 |
| Fujino, T | 1 |
| Nozawa, Y | 1 |
| Yamada, S | 1 |
| Shimizu, I | 2 |
| Kawashima, K | 2 |
| Ishii, D | 2 |
| Oka, M | 2 |
| Scheepe, JR | 1 |
| de Jong, BW | 1 |
| Wolffenbuttel, KP | 1 |
| Arentshorst, ME | 1 |
| Lodder, P | 1 |
| Kok, DJ | 1 |
| Ito, K | 1 |
| Iwami, A | 1 |
| Katsura, H | 1 |
| Ikeda, M | 1 |
| Klausner, AP | 1 |
| Sharma, S | 1 |
| Fletcher, S | 1 |
| Neff, P | 1 |
| Yang, SK | 1 |
| Son, H | 1 |
| Tuttle, JB | 1 |
| Steers, WD | 1 |
| Rivas, DA | 1 |
| Chancellor, MB | 1 |
| Huang, B | 3 |
| Salzman, SK | 1 |
| Sasaki, Y | 1 |
| Hamada, K | 1 |
| Yamazaki, C | 1 |
| Seto, T | 1 |
| Kimura, Y | 1 |
| Ukai, Y | 1 |
| Yoshikuni, Y | 1 |
| Kimura, K | 1 |
| Oka, T | 1 |
| Nakano, K | 1 |
| Kirimoto, T | 1 |
| Matsuura, N | 1 |
| Liu, X | 2 |
| Tan, L | 1 |
| Cui, Z | 1 |
| Yang, X | 1 |
| Jing, D | 1 |
| Zheng, D | 1 |
| Li, Z | 1 |
| Liang, Y | 1 |
| Zhu, S | 1 |
| Yeung, KWK | 1 |
| Wang, X | 1 |
| Zheng, Y | 1 |
| Wu, S | 1 |
| Ito, S | 1 |
| Hirobe, S | 1 |
| Kuwabara, Y | 1 |
| Nagao, M | 1 |
| Saito, M | 1 |
| Quan, YS | 1 |
| Kamiyama, F | 1 |
| Fujisawa, T | 1 |
| Okada, N | 1 |
| Yu, J | 2 |
| Wang, J | 1 |
| Zhang, Y | 1 |
| Chen, G | 1 |
| Mao, W | 1 |
| Ye, Y | 1 |
| Kahkoska, AR | 1 |
| Buse, JB | 1 |
| Langer, R | 1 |
| Gu, Z | 2 |
| Li, B | 1 |
| Huang, G | 1 |
| Ma, Z | 1 |
| Qin, S | 1 |
| Han, X | 1 |
| Li, H | 1 |
| Zhou, D | 1 |
| Chen, Z | 1 |
| Tamehiro, N | 1 |
| Adachi, R | 1 |
| Kondo, K | 1 |
| Arshad, MS | 1 |
| Zahra, AT | 1 |
| Zafar, S | 1 |
| Zaman, H | 1 |
| Akhtar, A | 1 |
| Ayaz, MM | 1 |
| Kucuk, I | 1 |
| Maniruzzaman, M | 1 |
| Chang, MW | 1 |
| Ahmad, Z | 1 |
| Vassilieva, EV | 1 |
| Li, S | 1 |
| Korniychuk, H | 1 |
| Taylor, DM | 1 |
| Wang, S | 1 |
| Prausnitz, MR | 1 |
| Compans, RW | 1 |
| Robb, KP | 1 |
| Cotechini, T | 1 |
| Allaire, C | 1 |
| Sperou, A | 1 |
| Graham, CH | 1 |
| Wang, YC | 1 |
| Bai, MY | 1 |
| Hsu, WY | 1 |
| Yu, MH | 1 |
| Kim, JH | 1 |
| Shin, JU | 1 |
| Kim, SH | 2 |
| Noh, JY | 1 |
| Kim, HR | 1 |
| Lee, J | 2 |
| Chu, H | 1 |
| Jeong, KY | 1 |
| Park, KH | 1 |
| Kim, JD | 1 |
| Kim, HK | 1 |
| Jeong, DH | 1 |
| Yong, TS | 1 |
| Park, JW | 1 |
| Lee, KH | 1 |
| Fukumoto, A | 1 |
| Tajima, K | 1 |
| Hori, M | 1 |
| Toda, Y | 1 |
| Kaku, S | 1 |
| Matsumoto, H | 1 |
| Yellon, DM | 1 |
| He, Z | 1 |
| Khambata, R | 1 |
| Ahluwalia, A | 1 |
| Davidson, SM | 1 |
| Wang, Y | 1 |
| Yu, X | 1 |
| Zhang, P | 1 |
| Ma, Y | 1 |
| Wang, L | 1 |
| Xu, H | 1 |
| Sui, D | 1 |
| Sibiya, N | 1 |
| Mabandla, M | 1 |
| Chablani, L | 1 |
| Tawde, SA | 1 |
| Akalkotkar, A | 1 |
| D'Souza, MJ | 1 |
| Zhang, X | 1 |
| Fang, Z | 1 |
| Cho, E | 1 |
| Huang, K | 1 |
| Zhao, J | 1 |
| Jiang, J | 1 |
| Huangfu, X | 1 |
| Majewska-Szczepanik, M | 1 |
| Góralska, M | 1 |
| Marcińska, K | 1 |
| Zemelka-Wiącek, M | 1 |
| Strzępa, A | 1 |
| Dorożyńska, I | 1 |
| Szczepanik, M | 1 |
| Ercan, N | 1 |
| Uludag, MO | 1 |
| Agis, ER | 1 |
| Demirel-Yilmaz, E | 1 |
| Davtyan, H | 1 |
| Ghochikyan, A | 1 |
| Hovakimyan, A | 1 |
| Petrushina, I | 1 |
| Flyer, D | 1 |
| Madsen, PJ | 1 |
| Pedersen, LO | 1 |
| Cribbs, DH | 1 |
| Agadjanyan, MG | 1 |
| Park, SY | 1 |
| Lee, HU | 1 |
| Lee, YC | 1 |
| Kim, GH | 1 |
| Park, EC | 1 |
| Han, SH | 1 |
| Lee, JG | 1 |
| Choi, S | 1 |
| Heo, NS | 1 |
| Kim, DL | 1 |
| Huh, YS | 1 |
| Chen, Y | 1 |
| Quan, P | 1 |
| Guo, W | 1 |
| Song, W | 1 |
| Cun, D | 1 |
| Wang, Z | 1 |
| Fang, L | 1 |
| Lee, SH | 1 |
| Noh, YH | 1 |
| Choi, BM | 1 |
| Noh, GJ | 1 |
| Park, WD | 1 |
| Kim, EJ | 1 |
| Cho, IH | 1 |
| Bae, CS | 1 |
| Parhi, R | 1 |
| Suresh, P | 1 |
| Patnaik, S | 1 |
| Mondoulet, L | 1 |
| Dioszeghy, V | 1 |
| Thébault, C | 1 |
| Benhamou, PH | 1 |
| Dupont, C | 1 |
| Ding, X | 1 |
| Sun, Y | 1 |
| Wang, Q | 1 |
| Pu, T | 1 |
| Li, X | 1 |
| Pan, Y | 1 |
| Yang, Y | 1 |
| Yoshihara, S | 1 |
| Fukuda, H | 1 |
| Abe, T | 1 |
| Arisaka, O | 1 |
| Adachi, H | 1 |
| Ioppolo, F | 1 |
| Paoloni, M | 1 |
| Santilli, V | 1 |
| Meier-Davis, SR | 1 |
| Dines, K | 1 |
| Arjmand, FM | 1 |
| Hamlin, R | 1 |
| Wen, J | 1 |
| Christianson, C | 1 |
| Shudo, J | 1 |
| Nagata, T | 1 |
3 reviews available for oxybutynin and Disease Models, Animal
| Article | Year |
|---|---|
Chronic pelvic ischemia: etiology, pathogenesis, clinical presentation and management.
Topics: Aged; Animals; Atherosclerosis; Calcium; Cell Hypoxia; Chronic Pain; Disease Models, Animal; Estroge | 2014 |
Epicutaneous immunotherapy for food allergy as a novel pathway for oral tolerance induction.
Topics: Administration, Cutaneous; Adolescent; Animals; Child; Child, Preschool; Clinical Trials as Topic; D | 2015 |
Physical characteristics, pharmacological properties and clinical efficacy of the ketoprofen patch: a new patch formulation.
Topics: Adhesiveness; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Chemistry, | 2011 |
41 other studies available for oxybutynin and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Gap junction expression and the effects of gap junction inhibitors in overactive bladder models: does ovariectomy have a role?
Topics: Analysis of Variance; Animals; Blotting, Western; Carbachol; Connexin 43; Disease Models, Animal; Fe | 2013 |
Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model.
Topics: Administration, Oral; Animals; Carbolines; Disease Models, Animal; Female; Mandelic Acids; Muscarini | 2015 |
Combinational effects of muscarinic receptor inhibition and β3-adrenoceptor stimulation on neurogenic bladder dysfunction in rats with spinal cord injury.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Disease Models, Animal; Drug Therapy, Co | 2017 |
Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis.
Topics: Adenosine Triphosphate; Animals; Benzhydryl Compounds; Benzofurans; Cresols; Cystitis; Disease Model | 2010 |
Urodynamics in a rat neurogenic bladder model with a unilateral electrolytic lesion of the basal forebrain.
Topics: Animals; Benzilates; Brain Diseases; Cholinergic Antagonists; Disease Models, Animal; Fumarates; Mal | 2003 |
The effect of oxybutynin on structural changes of the obstructed guinea pig bladder.
Topics: Animals; Disease Models, Animal; Guinea Pigs; Mandelic Acids; Parasympatholytics; Urinary Bladder Ne | 2007 |
Therapeutic effects of the putative P2X3/P2X2/3 antagonist A-317491 on cyclophosphamide-induced cystitis in rats.
Topics: Animals; Cyclophosphamide; Cystitis; Disease Models, Animal; Dose-Response Relationship, Drug; Femal | 2008 |
Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Behavior; Brain; | 2008 |
Autonomic dysreflexia in a rat model spinal cord injury and the effect of pharmacologic agents.
Topics: Adrenergic alpha-Antagonists; Animals; Autonomic Nervous System Diseases; Calcium Channel Blockers; | 1995 |
Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency.
Topics: Animals; Atropine; Benzilates; Calcium Channel Blockers; Denervation; Disease Models, Animal; Flavox | 1997 |
Effects of AH-9700, (+)-pentazocine, DTG and oxybutynin on micturition in anesthetized rats with acetone-induced cystitis.
Topics: Acetone; Anesthesia; Animals; Cystitis; Disease Models, Animal; Fumarates; Guanidines; Male; Mandeli | 2001 |
Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats.
Topics: Administration, Oral; Animals; Basal Nucleus of Meynert; Benzilates; Cognition Disorders; Consciousn | 2001 |
"Imitative" click chemistry to form a sticking xerogel for the portable therapy of bacteria-infected wounds.
Topics: Animals; Biocompatible Materials; Click Chemistry; Disease Models, Animal; Mice; Staphylococcal Infe | 2019 |
Immunogenicity of Milk Protein-Containing Hydrophilic Gel Patch for Epicutaneous Immunotherapy for Milk Allergy.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Cattle; Child; Child, Preschool; Disease Models, | 2020 |
Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Delivery Syste | 2020 |
Ultrasound-assisted transdermal delivery of alendronate for the treatment of osteoporosis.
Topics: Administration, Cutaneous; Alendronate; Animals; Biological Availability; Bone Density Conservation | 2020 |
Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Disease Models, Animal; Drug Delivery Systems; Extra | 2020 |
Assessment of Immune Responses in an Animal Model of Wheat Food Allergy via Epicutaneous Sensitization.
Topics: Administration, Cutaneous; Animals; Antigens, CD; Biomarkers; Disease Models, Animal; Female; Flour; | 2021 |
Antibiofilm Effects of Macrolide Loaded Microneedle Patches: Prospects in Healing Infected Wounds.
Topics: Administration, Cutaneous; Animals; Anti-Bacterial Agents; Azithromycin; Biofilms; Disease Models, A | 2021 |
cGAMP/Saponin Adjuvant Combination Improves Protective Response to Influenza Vaccination by Microneedle Patch in an Aged Mouse Model.
Topics: Adjuvants, Immunologic; Aging; Animals; Disease Models, Animal; Drug Delivery Systems; Female; Human | 2020 |
Inflammation-induced fetal growth restriction in rats is associated with increased placental HIF-1α accumulation.
Topics: Animals; Disease Models, Animal; Female; Fetal Growth Retardation; Gene Expression Regulation; Gesta | 2017 |
Evaluation of a series of silk fibroin protein-based nonwoven mats for use as an anti-adhesion patch for wound management in robotic surgery.
Topics: 3T3 Cells; Animals; Biocompatible Materials; Cell Adhesion; Cell Survival; Disease Models, Animal; F | 2018 |
Successful transdermal allergen delivery and allergen-specific immunotherapy using biodegradable microneedle patches.
Topics: Allergens; Animals; Dermatitis, Atopic; Dermatophagoides farinae; Desensitization, Immunologic; Dise | 2018 |
Analgesic effect of S (+)-flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E
Topics: Analgesics; Animals; Arthritis, Experimental; Dinoprostone; Disease Models, Animal; Dose-Response Re | 2018 |
The GTN patch: a simple and effective new approach to cardioprotection?
Topics: Administration, Cutaneous; Animals; Blood Pressure; Disease Models, Animal; Male; Mice, Inbred C57BL | 2018 |
Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Cutaneous; Animals; Apoptosis; Corpus | 2018 |
The pectin-insulin patch application prevents the onset of peripheral neuropathy-like symptoms in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Disease Progression; Hand Strength | 2018 |
Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin.
Topics: Administration, Cutaneous; Animals; Antigens, Neoplasm; Breast Neoplasms; Cancer Vaccines; Cell Line | 2019 |
Use of a Novel, Reinforced, Low Immunogenic, Porcine Small Intestine Submucosa Patch to Repair a Supraspinatus Tendon Defect in a Rabbit Model.
Topics: Animals; Connective Tissue; Disease Models, Animal; Humans; Intestinal Mucosa; Intestine, Small; Rab | 2019 |
Epicutaneous immunization with protein antigen TNP-Ig alleviates TNBS-induced colitis in mice.
Topics: Administration, Cutaneous; Animals; Biomarkers; Cells, Cultured; Colitis; Colon; Desensitization, Im | 2012 |
The anti-inflammatory effect of diclofenac is considerably augmented by topical capsaicinoids-containing patch in carrageenan-induced paw oedema of rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsaicin; Capsicum; Carrageenan; Diclofenac; Dise | 2013 |
Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines.
Topics: Adjuvants, Immunologic; Alzheimer Vaccines; Amyloid beta-Peptides; Animals; Antibodies, Viral; Bacte | 2014 |
Wound healing potential of antibacterial microneedles loaded with green tea extracts.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Camellia sinensis; CHO Cells; Cricet | 2014 |
Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutic | 2015 |
Pharmacokinetics of Memantine after a Single and Multiple Dose of Oral and Patch Administration in Rats.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Alzheimer Disease; Ani | 2016 |
Application of Response Surface Methodology for Design and Optimization of Reservoir-type Transdermal Patch of Simvastatin.
Topics: Administration, Cutaneous; Animals; Biomarkers; Cyclohexenes; Disease Models, Animal; Drug Compoundi | 2016 |
Pharmacokinetics and pharmacodynamics of glycyrrhetinic acid with Paeoniflorin after transdermal administration in dysmenorrhea model mice.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Synergism | 2016 |
Comparative study of skin permeation profiles between brand and generic tulobuterol patches.
Topics: Animals; Asthma; Bronchodilator Agents; Disease Models, Animal; Drugs, Generic; Female; Patents as T | 2010 |
Comparison of oral and transdermal administration of rasagiline mesylate on human melanoma tumor growth in vivo.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Ani | 2012 |